Venetoclax in combination recommended for chronic lymphocytic leukaemia
Venetoclax plus obinutuzumab is recommended as an option for untreated chronic lymphocytic leukaemia in final NICE guidance.
Published
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date